Literature DB >> 32502457

Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.

Jason Fangusaro1, Olaf Witt2, Pablo Hernáiz Driever3, Asim K Bag4, Peter de Blank5, Nadja Kadom6, Lindsay Kilburn7, Robert M Lober8, Nathan J Robison9, Michael J Fisher10, Roger J Packer11, Tina Young Poussaint12, Ludmila Papusha13, Shivaram Avula14, Alba A Brandes15, Eric Bouffet16, Daniel Bowers17, Anton Artemov13, Murali Chintagumpala18, David Zurakowski19, Martin van den Bent20, Brigitte Bison21, Kristen W Yeom22, Walter Taal23, Katherine E Warren24.   

Abstract

Paediatric low-grade gliomas (also known as pLGG) are the most common type of CNS tumours in children. In general, paediatric low-grade gliomas show clinical and biological features that are distinct from adult low-grade gliomas, and the developing paediatric brain is more susceptible to toxic late effects of the tumour and its treatment. Therefore, response assessment in children requires additional considerations compared with the adult Response Assessment in Neuro-Oncology criteria. There are no standardised response criteria in paediatric clinical trials, which makes it more difficult to compare responses across studies. The Response Assessment in Pediatric Neuro-Oncology working group, consisting of an international panel of paediatric and adult neuro-oncologists, clinicians, radiologists, radiation oncologists, and neurosurgeons, was established to address issues and unique challenges in assessing response in children with CNS tumours. We established a subcommittee to develop consensus recommendations for response assessment in paediatric low-grade gliomas. Final recommendations were based on literature review, current practice, and expert opinion of working group members. Consensus recommendations include imaging response assessments, with additional guidelines for visual functional outcomes in patients with optic pathway tumours. As with previous consensus recommendations, these recommendations will need to be validated in prospective clinical trials.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID: 32502457     DOI: 10.1016/S1470-2045(20)30064-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  25 in total

Review 1.  European Society for Paediatric Oncology (SIOPE) MRI guidelines for imaging patients with central nervous system tumours.

Authors:  Shivaram Avula; Andrew Peet; Giovanni Morana; Paul Morgan; Monika Warmuth-Metz; Tim Jaspan
Journal:  Childs Nerv Syst       Date:  2021-05-10       Impact factor: 1.475

2.  Targeted therapy for pediatric low-grade glioma.

Authors:  Juan Pablo Muñoz Pérez; Jordi Muchart; Vicente Santa-María López; Mariona Suñol Capella; Noelia Salvador; Sara Pérez Jaume; Ofelia Cruz Martínez; Andrés Morales La Madrid
Journal:  Childs Nerv Syst       Date:  2021-04-17       Impact factor: 1.475

3.  ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium.

Authors:  S Vajapeyam; D Brown; A Ziaei; S Wu; G Vezina; J S Stern; A Panigrahy; Z Patay; B Tamrazi; J Y Jones; S S Haque; D S Enterline; S Cha; B V Jones; K W Yeom; A Onar-Thomas; I J Dunkel; M Fouladi; J R Fangusaro; T Y Poussaint
Journal:  AJNR Am J Neuroradiol       Date:  2022-02-24       Impact factor: 3.825

4.  Comparison of intraoperative and post-operative 3-T MRI performed at 24-72 h following brain tumour resection in children.

Authors:  Shivaram Avula; Tim Jaspan; Barry Pizer; Benedetta Pettorini; Deborah Garlick; Dawn Hennigan; Conor Mallucci
Journal:  Neuroradiology       Date:  2021-02-25       Impact factor: 2.804

5.  Diagnostic accuracy and clinical impact of [18F]FET PET in childhood CNS tumors.

Authors:  Lisbeth Marner; Michael Lundemann; Astrid Sehested; Karsten Nysom; Lise Borgwardt; René Mathiasen; Peder S Wehner; Otto M Henriksen; Carsten Thomsen; Jane Skjøth-Rasmussen; Helle Broholm; Olga Østrup; Julie L Forman; Liselotte Højgaard; Ian Law
Journal:  Neuro Oncol       Date:  2021-12-01       Impact factor: 12.300

6.  A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.

Authors:  Jason Fangusaro; Arzu Onar-Thomas; Tina Young Poussaint; Shengjie Wu; Azra H Ligon; Neal Lindeman; Olivia Campagne; Anu Banerjee; Sridharan Gururangan; Lindsay B Kilburn; Stewart Goldman; Ibrahim Qaddoumi; Patricia Baxter; Gilbert Vezina; Corey Bregman; Zoltan Patay; Jeremy Y Jones; Clinton F Stewart; Michael J Fisher; Laurence Austin Doyle; Malcolm Smith; Ira J Dunkel; Maryam Fouladi
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 12.300

7.  Trametinib therapy for children with neurofibromatosis type 1 and life-threatening plexiform neurofibroma or treatment-refractory low-grade glioma.

Authors:  Rebecca Ronsley; Celine D Hounjet; Sylvia Cheng; Shahrad Rod Rassekh; Walter J Duncan; Christopher Dunham; Jane Gardiner; Arvindera Ghag; Jeffrey P Ludemann; David Wensley; Wingfield Rehmus; Michael A Sargent; Juliette Hukin
Journal:  Cancer Med       Date:  2021-05-03       Impact factor: 4.452

8.  Survival and functional outcomes in paediatric thalamic and thalamopeduncular low grade gliomas.

Authors:  Vladimír Beneš; Michal Zápotocký; Petr Libý; Jakub Táborský; Jana Blažková; Jana Blažková; David Sumerauer; Adéla Mišove; Ivana Perníková; Martin Kynčl; Lenka Krsková; Miroslav Koblížek; Josef Zámečník; Ondřej Bradáč; Michal Tichý
Journal:  Acta Neurochir (Wien)       Date:  2022-01-19       Impact factor: 2.216

Review 9.  Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.

Authors:  Robert Galvin; Adrienne L Watson; David A Largaespada; Nancy Ratner; Sara Osum; Christopher L Moertel
Journal:  Curr Oncol Rep       Date:  2021-03-15       Impact factor: 5.075

Review 10.  The Role of PET in Supratentorial and Infratentorial Pediatric Brain Tumors.

Authors:  Angelina Cistaro; Domenico Albano; Pierpaolo Alongi; Riccardo Laudicella; Daniele Antonio Pizzuto; Giuseppe Formica; Cinzia Romagnolo; Federica Stracuzzi; Viviana Frantellizzi; Arnoldo Piccardo; Natale Quartuccio
Journal:  Curr Oncol       Date:  2021-07-05       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.